Join our daily newsletter At The Bell to receive exclusive market insights
- BARD1 Life Sciences (BD1) has been served with a writ and statement of claim from within its own ranks
- The original founders and major shareholders of company subsidiary BARD1AG SA, have commenced legal proceedings against BARD1 in Victoria’s Supreme Court
- The proceedings relate to performance shares, which were issued to the founders and shareholders when BARD1 first acquired BARD1AG
- The company plans to file a comprehensive defence against the proceedings in due course
- BARD1 Life Sciences is down 3.79 per cent and trading at $3.05 per share
BARD1 Life Sciences (BD1) has been served with a writ and statement of claim from within its own ranks.
Tony Walker and Dr Irmgard Irminger-Finger have commenced legal proceedings against the company, in the Supreme Court of Victoria. They have done so on behalf of the plaintiff group they are a part of, which includes the original founders and major shareholders of BARD1AG SA.
BARD1AG is a wholly owned subsidiary of BARD1, which was acquired from the plaintiffs in 2016.
The legal proceedings relate to performance shares, which were issued to the plaintiffs when BARD1 first acquired BARD1AG. Dr Irminger-Finger currently holds a total of 3,608,414 performance shares, while Tony Walker holds 2,950,055.
As part of the agreement to acquire BARD1AG, BARD1 issued founders and major shareholders with performance shares, which had the potential to be converted into ordinary shares in the company. However, this was subject to certain milestones being achieved before the expiry date of June 9, 2021.
This referred specifically to milestones related to the development of the company’s lung cancer test.
While the expiration date for the performance shares has not yet passed, the plaintiffs are claiming that BARD1 deprived them of the opportunity to meet the milestones in time. Their statement of claim to the Supreme Court alleges that BARD1 had an obligation to do what was reasonably necessary to ensure that the lung cancer test satisfied the milestones, so as not to deny the plaintiffs the conversion of performance shares to ordinary shares.
The legal proceedings are seeking damages, costs, interest and any other compensation the Court deems just from BARD1.
The company plans to file a comprehensive defence against the proceedings in due course and has chosen not to comment on the issue for now.
BARD1 Life Sciences is down 3.79 per cent, trading at $3.05 per share at 10:50 am AEDT.
